METHODS FOR USE OF BISPECIFIC ANTIBODY THAT RECOGNIZES CLOTTING FACTOR IX AND/OR ACTIVATED CLOTTING FACTOR IX AND CLOTTING FACTOR X AND/OR ACTIVATED CLOTTING FACTOR X Russian patent published in 2022 - IPC A61K39/395 A61P7/04 C07K16/00 C07K16/36 

FIELD: biotechnology.

SUBSTANCE: method for the treatment and/or reduction in the incidence of a disease that develops and/or progresses due to a decrease or deficiency in the activity of blood clotting factor VIII and/or activated blood clotting factor VIII (FVIIIa) is described. The method includes stages of administration to an individual of a bispecific antibody that recognizes (a) blood clotting factor IX and/or activated blood clotting factor IX and (b) blood clotting factor X and/or activated blood clotting factor X, weekly at an initial antibody dose of 3 mg/kg for four weeks, and administration to a subject of a bispecific antibody at a subsequent maintenance dose of 6 mg/kg of antibody every four weeks in the form of a single dose or several divided doses, where the bispecific antibody is emicizumab.

EFFECT: invention expands the arsenal of methods for the treatment of diseases that depend on FVIII and/or FVIIIa.

5 cl, 13 dwg, 6 tbl, 7 ex